Sort   by:  
 Page size 
UnknownSecond-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.
Not available
S-EPMC3293714 | biostudies-literature
UnknownA phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer.
Not available
S-EPMC3630482 | biostudies-literature
UnknownQuality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial.
Not available
S-EPMC9081717 | biostudies-literature
UnknownEfficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
Not available
S-EPMC5654161 | biostudies-literature
UnknownCorrelation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
Not available
S-EPMC4959928 | biostudies-literature
UnknownTumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Not available
S-EPMC11702314 | biostudies-literature
UnknownSelpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
Not available
S-EPMC9839260 | biostudies-literature
UnknownEffect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Not available
S-EPMC7139275 | biostudies-literature
UnknownFirst-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC.
Not available
S-EPMC10698285 | biostudies-literature
UnknownEfficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Not available
S-EPMC5731244 | biostudies-literature
Sort   by:  
 Page size